ATAI

Q: What is the price of ATAI Life Sciences BV (ATAI) today?

The current price of ATAI Life Sciences BV (ATAI) is $ 4.09, representing a 99.51% gain over the past year. The stock began the year trading around $ 4.09 and is currently priced at $ 4.09. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

Q: When does ATAI Life Sciences BV (ATAI) pay dividends?

ATAI Life Sciences BV (ATAI) did not pay dividends over the past year.

ATAI Life Sciences BV

Price

$ 4.09

return (12m)

99.51%

p/e

-2.23

p/bv

7.45

DIVIDEND YIELD

0.00%

ATAI price

ATAI

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

15 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return on Investment ATAI

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-16.53%

3 months

7.07%

1 year

99.51%

2 years

136.42%

5 years

0.00%

10 years

0.00%

Fundamentals ATAI

review the fundamentals of ATAI Life Sciences BV shares

P/E

-2.23

Sector: 7.44 Industry: 7.44

P/S (PSR)

424.51

Sector: 2.26 Industry: 2.26

P/BV

7.45

Sector: 2.14 Industry: 2.14

DIVIDEND YIELD (DY)

0.00%

Sector: 0.66% Industry: 0.66%

ROA

-250.45%

Sector: -0.35% Industry: -0.35%

ROE

-333.73%

Sector: 3.58% Industry: 3.58%

ROIC

-584.19%

Sector: -163.14% Industry: -163.14%

NET MARGIN

-100.00%

Sector: 3.18% Industry: 3.18%

GROSS MARGIN

100.00%

Sector: 31.95% Industry: 31.95%

OPERATING MARGIN

-100.00%

Sector: 4.99% Industry: 4.99%

EV/EBITDA

-2.24

Sector: 3.01 Industry: 3.01

EV/EBIT

-2.23

Sector: 1.54 Industry: 1.54

PRICE-TO-ASSETS

5.59

Sector: 1.01 Industry: 1.01

BVPS

0.56

Sector: 10.19 Industry: 10.19

EPS

-1.86

Sector: 0.69 Industry: 0.69

EQUITY-TO-ASSETS RATIO

0.75

Sector: 0.43 Industry: 0.43

LIABILITIES / ASSETS

0.25

Sector: 0.53 Industry: 0.53

CAGR REVENUE 5 YEARS

-29.74%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

31.64%

Sector: - Industry: -

Fundamentals ATAI

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
META	21.94	6.36	28.97%	0.34%	$ 1.55 T	32.84%
INTR	1.92	1.42	73.90%	1.83%	$ 2.75 B	9.10%
PBR	6.50	1.55	23.78%	5.83%	$ 131.89 B	21.75%
VALE	24.42	1.85	7.59%	6.21%	$ 69.63 B	7.21%
PLTR	141.80	37.81	26.67%	0.00%	$ 323.53 B	43.67%
SHEL	13.24	1.42	10.74%	3.29%	$ 248.24 B	7.01%
BDORY	10.04	0.62	6.21%	2.80%	$ 23.46 B	8.65%
MAIN	10.88	1.50	13.78%	7.81%	$ 4.64 B	81.08%
NSRGY	11.04	6.22	56.41%	3.38%	$ 258.23 B	10.91%
ENB	24.16	2.46	10.18%	4.89%	$ 121.41 B	10.01%
PBR-A	5.84	1.39	23.78%	5.86%	$ 118.50 B	21.75%
ITUB	53.55	10.81	20.18%	1.98%	$ 87.48 B	12.16%
UNH	29.49	3.37	11.44%	2.26%	$ 355.15 B	2.68%
BBSEY	7.98	5.62	70.42%	11.47%	$ 13.59 B	100.00%
SAN	9.57	1.38	14.44%	1.71%	$ 179.71 B	27.40%
TTE	13.16	1.59	12.05%	6.13%	$ 198.59 B	8.20%
RACE	30.91	12.26	39.66%	1.31%	$ 57.45 B	22.18%
IONQ	55.90	3.67	6.56%	0.00%	$ 18.29 B	100.00%
TD	11.61	2.00	17.19%	2.84%	$ 182.08 B	34.54%

Stock vs Indice Comparison Tool

If you had invested

years ago

2 years

5 years

10 years

ago, you would now have *

ago, you would now have:

*The value considers the reinvestment of dividends.

ATAI Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT ATAI Life Sciences BV

ATAI Life Sciences BV

Average Investor10 user rating

4.0 (3 people)

United States

- year

Founded:

Time since IPO - - year

-

Employees

ATAI Life Sciences N.V. (ATAI) is a biotechnology company focused on developing novel therapies for mental health disorders, with an emphasis on psychedelic-based treatments and next-generation compounds.

The company operates through a decentralized model, supporting multiple clinical programs via subsidiaries and strategic partnerships.

Its main activities include:

• Research and development of treatments for depression, anxiety and other mental health conditions.
• Clinical trials across multiple regulatory stages.
• Investments in biotech platforms and early-stage companies.
• Partnerships with research institutions and pharmaceutical firms.

ATAI operates globally, with activities across Europe and the United States, targeting areas of high unmet medical need.

Its performance is influenced by clinical trial outcomes, regulatory approvals, scientific advancements and biotech funding conditions.

ATAI Life Sciences N.V. trades on the Nasdaq under the ticker ATAI.

History and Development

ATAI Life Sciences N.V. was founded in 2018 to accelerate the development of innovative mental health treatments.

Since its inception, the company has built a diversified pipeline of clinical programs focused on disruptive therapeutic approaches.

ATAI went public in 2021 on the Nasdaq, expanding its access to capital and supporting research growth.

In recent years, the company has advanced clinical trials and strengthened strategic partnerships, positioning itself within the emerging mental health biotech space.

Additional Information

ATAI Life Sciences BV (United States) is listed on the Nasdaq and has a market capitalization of $1.48 Billion, with shareholders equity totaling $198.78 Millions.

The Company is listed on the [MARKET_NAME]

Over the past 12 months, ATAI Life Sciences BV reported $3.49 Millions in revenue, generating net income of $-663.39 Millions.

Key financial metrics include a P/E ratio of -2.23, a price-to-book (P/B) ratio of 7.45, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ATAI.

Market cap

$ 1.48 Billion

Net worth

$ 198.78 Millions

$ 198,780,000.00

Assets

$ 264.88 Millions

$ 264,880,000.00

Total Shares Outstanding

357.00 Millions

357,000,000

Average Daily Trading Volume

$ 5.70 Millions

$ 5,701,146.72

Sector

Others

Industry

Others

ATAI

ATAI revenue and profits

Financial Results ATAI

DRAG THE FRAME TO SEE MORE DATA

ATAI cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

SHG - Shinhan Financial Group Co Ltd

$ 64.22 70,42% (12M)

P/E

0.01

2.47%

ROE

7.11%

P/BV

0.00

CRERF - Carrefour SA

$ 20.10 35,92% (12M)

P/E

1.28

6.35%

ROE

9.46%

P/BV

0.12

UNH - UnitedHealth Group Incorporated

$ 383.30 32,81% (12M)

P/E

29.49

2.26%

ROE

11.44%

P/BV

3.37

STLA - Stellantis NV

$ 7.53 --27,25% (12M)

P/E

-1.06

0.00%

ROE

-32.04%

P/BV

0.34

CCOEY - Capcom Co Ltd ADR

$ 10.11 --27,47% (12M)

P/E

0.14

1.50%

ROE

20.55%

P/BV

0.03

COR - Cencora Inc.

$ 264.75 --7,87% (12M)

P/E

19.99

0.88%

ROE

71.09%

P/BV

14.21

SHEL - Shell PLC ADR

$ 86.72 37,99% (12M)

P/E

13.24

3.29%

ROE

10.74%

P/BV

1.42

SSNLF - Samsung Electronics Co Ltd

$ - -0,00% (12M)

P/E

19.25

1.58%

ROE

10.38%

P/BV

2.00